qRare International, LLC

03/30/2026

https://www.linkedin.com/posts/qrareintl_global-excellence-awards-rare-genetic-disorder-activity-7444339431307657216-Brp9

03/04/2026

https://www.linkedin.com/feed/update/urn:li:activity:7434671929866813440

03/04/2026

[Eyes: Windows of The Genome!]

Introducing our upcoming RIGHT “Dysmorphology Visual Art” flashcard mini-series, where there is more to the eyes than meets the eye!!

11/04/2025

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-1st-drug-thymidine-kinase-2-deficiency-very-rare-mitochondrial-disease?utm_medium=email&utm_source=govdelivery

05/06/2025

09/14/2022

We’re thrilled to further share this fantastic news!
This represents an important step in the journey towards 'realizing' what was perhaps once considered 'just a dream’ for many patients and families with alpha mannosidosis in the US!

/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group),...

08/25/2022

Throughout the journey of having a rare genetic disease, we believe that:
- Clinical Diagnosis alone is not enough
- Molecular Diagnosis alone is not enough
- Clinical Research alone is not enough
- Drug Development alone is not enough

Our mission is to build a clear path across these ‘stops’; the rare disease community deserves that.